Table: Anges - 9-MTH group results
Nov 8 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2023 Sep 30, 2022 Dec 31, 2023
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 102 mln 45 mln 190 mln
(+123.6 pct) (+3.1 pct) (+183.3 pct)
Operating loss 9.21 loss 12.46 loss 13.50
Recurring loss 4.72 loss 10.06 loss 7.50
Net loss 4.80 loss 10.19 loss 7.50
EPS loss 25.69 yen loss 66.60 yen loss 39.78 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001